EP300 and leukemia: Moreover, SE activity of TCF3-HLF is mediated through the recruitment of EP300; thus, BRD4 inhibitor JQ1 and EP300 inhibitor A-485 are two reasonable options for TCF3-HLF-fusion leukemia [112].